GlassScriptPhysician profile
Laura Kyle Brett
NPI 1235398066
$981.69
in general payments reported to CMS, 2019-2025
16 companies · $233 in 2025
The $233 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25.82 · 2021: $193 · 2022: $91.63 · 2023: $175 · 2024: $264 · 2025: $233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $342 · Education: $329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $341.81 |
| Education | $329.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $434.32 | 2019-2025 | |
| Inari Medical, INC. | $181.24 | 2021 | |
| Abbvie INC. | $61.28 | 2024-2025 | |
| Acrotech Biopharma INC. | $49.54 | 2022-2024 | Beleodaq |
| Astellas Pharma US INC | $39.73 | 2024-2025 | Vyloy |
| Celgene Corporation | $33.34 | 2025 | Reblozyl |
| Ipsen Biopharmaceuticals, INC | $32.46 | 2024 | Onivyde, Tazverik |
| Janssen Scientific Affairs, LLC | $20.55 | 2025 | Tecvayli, Talvey |
| Myriad Genetic Laboratories, INC. | $19.64 | 2024 | Myrisk |
| Progenics Pharmaceuticals, INC. | $19.30 | 2025 | |
| Incyte Corporation | $18.66 | 2023 | Monjuvi |
| E.R. Squibb & Sons, L.L.C. | $15.71 | 2025 | Eliquis |
| Penumbra, INC. | $15.15 | 2023 | Indigo System |
| Glaxosmithkline, LLC. | $14.53 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $14.32 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Brett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.